Improving venous symptoms in C0s-C1s patients after multicomponent diosmin-based preparation: Initial experience

Abstract

The use of drug therapies in patients with chronic venous disease (CVD) remains a topic of debate regarding safety, compliance, and effectiveness. Although the beneficial effects of molecules like diosmin have been established in patients with chronic venous insufficiency (CVI) of C3–C6 classes, the evidence for its use in C0–C1 patients is not well documented. This report aims to describe and analyze the positive impact of a new diosmin-based drug therapy on a population of C0–C1 patients in terms of relief of venous symptoms.

Keywords

Venoactive drugs quality of life CEAP chronic venous disease venous symptoms

Get full access to this article

View all access options for this article.

References

Gianesini

Obi

Onida

, et al. Global guidelines trends and controversies in lower limb venous and lymphatic disease: narrative literature revision and experts' opinions following the vWINter international meeting in Phlebology, Lymphology & Aesthetics, 23-25 January 2019. Phlebology 2019; 34(1 Suppl): 4–66.

Rabe

Guex

Puskas

, et al. Epidemiology of chronic venous disorders in geographically diverse populations: results from the vein consult program. Int Angiol 2012; 31(2): 105–115.

Maggioli

Carpentier

. Efficacy of MPFF 1000 mg oral suspension on CVD C0s-C1-related symptoms and quality of life. Int Angiol 2019; 38(2): 83–89.

Perrin

Eklof

VAN Rij

, et al. Venous symptoms: the SYM vein consensus statement developed under the auspices of the European venous forum. Int Angiol 2016; 35(4): 374–398.

Kakkos

Nicolaides

. Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials. Int Angiol 2018; 37(2): 143–154.

Russo

Chandradhara

De Tommasi

. Comparative bioavailability of two diosmin formulations after oral administration to healthy volunteers. Molecules 2018; 23(9): 2174.

Serra

Ielapi

Bitonti

, et al. Efficacy of a low-dose diosmin therapy on improving symptoms and quality of life in patients with chronic venous disease: randomized, double-blind, placebo-controlled trial. Nutrients 2021; 13(3): 999.

Nicolaides

Kakkos

Baekgaard

, et al. Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Part I. Int Angiol 2018; 37(3): 181–254.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.48 MB